Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05153434
PHASE2

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Sponsor: Aardvark Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome

Official title: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome (PWS)

Key Details

Gender

All

Age Range

17 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

19

Start Date

2022-05-27

Completion Date

2024-09-24

Last Updated

2026-09-08

Healthy Volunteers

No

Interventions

DRUG

ARD-101

Oral administration of ARD-101 taken BID (twice daily) for 28 days.

Locations (2)

Stanford University

Palo Alto, California, United States

Children's Hospital Colorado

Aurora, Colorado, United States